News
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today introduced three new microarrays to meet the needs of cytogenetic laboratories conducting both prenatal and postnatal ...
Use of Agilent’s custom microarrays in the SOMAscan® assay will help drive biomarker discovery efforts as well as novel diagnostics and accelerated pharmaceutical development SANTA CLARA, Calif. & ...
Two companies will provide an end-to-end solution tailored to application services. Oxford Gene Technology (OGT) and Agilent Technologies completed a collaborative agreement giving OGT access to ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced that the United States-Latin American Cancer Research Network (US-LACRN) has selected Agilent Gene Expression ...
PALO ALTO, Calif., Jan. 5, 2005 -- Agilent Technologies Inc. (NYSE: A) today announced a breakthrough development that enables the rapid advance of microarray-based comparative genomic studies in ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) announced it has obtained clearance from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the GenetiSure Dx ...
Agilent’s SurePrint microarray technology features a flexible, industrial-scale inkjet printing process that synthesizes oligonucleotide probes in situ onto 1“ x 3“ slides. The maskless process allows ...
Agilent Technologies Inc. and Beckman Coulter Genomics, Inc. have announced that Beckman Coulter Genomics has achieved Certified Service Provider (CSP) status for the Agilent SureSelect Target ...
The State of the Microarray | Selected Suppliers of Microarray Chips, Spotters, and Readers Courtesy of Amersham Biosciences Note: a = arrays; r = reader; s = spotter Affymetrix www.affymetrix.com - a ...
The "Microarray Analysis Market by Product & Service (Consumables, Instrument, Software, Services), Type, Application (Research), End User (Diagnostic Laboratories, Pharmaceutical & Biotechnology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results